Metocard-CHT 25 Tablet ER is a combination antihypertensive medication containing Chlorthalidone (12.5 mg), Metoprolol Succinate (25 mg), and Telmisartan (40 mg). This formulation is designed for extended-release administration to provide sustained blood pressure control in patients with hypertension. Chlorthalidone, a thiazide-like diuretic, promotes diuresis and reduces plasma volume, thereby lowering blood pressure. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, contributing to antihypertensive effects and cardioprotection. Telmisartan, an angiotensin II receptor blocker (ARB), inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure. The combination targets multiple pathways involved in hypertension, enhancing efficacy compared to monotherapy. Metocard-CHT 25 is indicated for the management of essential hypertension, especially in patients requiring multiple agents for adequate blood pressure control. It may also benefit patients with comorbid conditions such as heart failure or ischemic heart disease. Therapy should be individualized, and patients monitored for potential adverse effects including electrolyte imbalance, bradycardia, hypotension, and renal function alterations. This medication should be used under medical supervision with appropriate dose adjustments based on clinical response.